Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOK002 in advanced solid tumors
NCT07612189Phase 1Recruiting
- Sponsor
- NEOK Bio
- Start
- Apr 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of NEOK002 in solid tumor (2 arms), sponsored by NEOK Bio. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 32 months and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
NEOK002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07612189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612189.